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Available online xxxxComputerized tests beneﬁt from automated scoring procedures and standardized administration instructions.
These methods can reduce the potential for rater error. However, especially in patients with severe mental ill-
nesses, the equivalency of traditional and tablet-based tests cannot be assumed. The Brief Assessment of Cogni-
tion in Schizophrenia (BACS) is a pen-and-paper cognitive assessment tool that has been used in hundreds of
research studies and clinical trials, and has normative data available for generating age- and gender-corrected
standardized scores. A tablet-based version of the BACS called the BAC App has been developed. This study com-
pared performance on the BACS and the BAC App in patientswith schizophrenia and healthy controls. Test equiv-
alency was assessed, and the applicability of paper-based normative data was evaluated. Results demonstrated
the distributions of standardized composite scores for the tablet-based BAC App and the pen-and-paper BACS
were indistinguishable, and the between-methods mean differences were not statistically signiﬁcant. The dis-
crimination between patients and controls was similarly robust. The between-methods correlations for individ-
ual measures in patients were r N 0.70 for most subtests.When data from the TokenMotor Test was omitted, the
between-methods correlation of composite scores was r= 0.88 (df = 48; p b 0.001) in healthy controls and r=
0.89 (df = 46; p b 0.001) in patients, consistent with the test-retest reliability of each measure. Taken together,
results indicate that the tablet-based BAC App generates results consistent with the traditional pen-and-paper
BACS, and support the notion that the BAC App is appropriate for use in clinical trials and clinical practice.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cognitive deﬁcits in schizophrenia can be severe and devastating to
patients and their families. People with schizophrenia underperform
controls by an estimated one and a half to two standard deviations on
multiple aspects of cognitive functioning (Nuechterlein et al., 2008).
Cognitive impairment in schizophrenia is an important unmet medical
need, and is the target of numerous treatment efforts (Keefe et al.,
2011a,b, 2013; Wykes et al., 2011; Goff et al., 2011).
A variety of methods have been used to measure cognition in pa-
tients with schizophrenia in clinical practice and clinical trials. Standard
neuropsychological tests have been used for decades to measure cogni-
tion in patients with schizophrenia. These standard clinical measuresy Medical Center, Durham, NC
.
. This is an open access article under
lidation of the tablet-adminis
0have the beneﬁt of provenmethodologies and patient-rater interaction,
which can be ﬂexible based upon the needs of the patient and the clin-
ical situation. In schizophrenia research, these measures have demon-
strated sensitivity to impairments and consistent correlations with
functional outcomes, which has been one of the key driving forces of in-
terest in cognition as a treatment target.
Compared to traditional pen-and-paper neurocognitive assess-
ments, computerized tests carry the potential to reduce rater error by
leveraging automated scoring algorithms and standardized administra-
tor instructions. However, especially in patients with severe mental ill-
nesses and neurologic disorders, computerized tests can be difﬁcult to
implement due to the rigidity of their administration procedures and re-
duced adaptability to individual patient needs and understanding.
These limitations have sometimes resulted in increased rates of missing
data for computerized tests relative to standard paper methods (Silver
et al., 2006; Harvey et al., 2013; Keefe et al., 2007a,b; Iverson et al.,
2009). Further, because computerized tests tend to be more abstractthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tered Brief Assessment of Cognition (BACApp), Schizophr. Res. (2016),
Table 1
Sample demographics.
Parameter Patients (n = 48) Healthy controls (n = 50) p value
Age 46.04 ± 13.18 48.26 ± 14.52 ns
Education 12.63 ± 1.65 15.12 ± 2.55 b0.001
Maternal education 12.47 ± 3.51 13.43 ± 2.64 ns
Sex (% male) 52% 50% ns
Race (% white) 74% 79% ns
All table entries aremean±SD or %. Continuous variableswere compared by independent
t-test and the categorical variables were compared by Fisher's exact test. All p-values are
non-signiﬁcant (α N 0.1) except for Education (p b 0.001).
2 A.S. Atkins et al. / Schizophrenia Research xxx (2016) xxx–xxxthan paper tests with physical materials, severely impaired populations
may struggle to understand test requirements (Iverson et al., 2009).
One potential solution for impaired populations that may combine
the strengths of both traditional pen-and-paper and computerized test-
ing platforms is a streamlined tablet-based interface that combines the
ﬂexibility and human interaction of standard methods with the consis-
tency and automaticity of computerized methods. Tablet-based ver-
sions of other standard cognitive assessment instruments such as the
Wechsler Adult and Child Intelligence Scales (Wechsler, 2003, 2008)
have been developed and are in use in clinical practice.
The Brief Assessment of Cognition in Schizophrenia (Keefe et al.,
2004) was developed as a quick and effective tool for the assessment
of cognitive change in schizophrenia. The BACS comprises six tasks for
the evaluation of 4 cognitive domains identiﬁed as important for clinical
trials in schizophrenia by the MATRICS Neurocognition Committee
(Nuechterlein et al., 2004), including verbalmemory, workingmemory,
processing speed, and reasoning/problem solving. The composite score
has high test-retest reliability in patients with schizophrenia and
healthy controls (ICCs N 0.80), has been shown to be as sensitive to
the cognitive deﬁcits of schizophrenia as a standard 2.5-hour battery
(Keefe et al., 2004) and is highly correlated (r = 0.84, p b 0.001) with
the composite score derived from the CATIENeurocognitive Test Battery
(Keefe et al., 2007a,b; Hill et al., 2008). The BACShas clear functional rel-
evance, as evidenced by strong correlations between the composite
score and functional measures such as independent living skills (r =
0.45), performance-based assessments of performance of everyday liv-
ing skills (r = 0.56), and interview-based assessments of cognition in
patients with schizophrenia (r = 0.48; Keefe et al., 2006). It has also
demonstrated sensitivity to treatment (Bowie et al., 2012; Geffen et
al., 2012). The original BACS has been adapted for use for indications be-
yond schizophrenia (Keefe et al., 2014), and in this context is referred to
simply as the BAC (Brief Assessment of Cognition). Normative data
based upon 400 healthy participants demographically matched to the
US Census (Keefe et al., 2008) allow for calculation of standardized do-
main scores and overall composite scores with correction for age and
gender.
The BAC Appwas developed to allow tablet-based delivery and scor-
ing of all subtests included in the original pen and Paper BAC/BACS in-
strument, which we will refer to here as the Paper BAC. The test
battery can be administered in full or with individual tests to yield sub-
test and total scores with normative results. Like the original instru-
ment, the BAC App assesses multiple cognitive domains. By ensuring
standardized administration of instructions and test stimuli, the BAC
App allows for reduction in error variance due to rater inconsistencies,
and provides automated scoring. Results can be immediately reviewed
on the tablet device, or transferred to a central data repository for
later analysis.
The primary aimof the present validation studywas to assess the va-
lidity of the BAC App as a measure of cognitive function by comparing
performance and psychometric characteristics of the BAC App with
the original Paper BAC in the same group of participants. In order to as-
sess test equivalency and determine the sensitivity of the BAC App to
cognitive deﬁcits in schizophrenia, healthy controls and patients with
schizophrenia completed the BAC App and Paper BAC within a single
visit.
2. Methods
2.1. Participants
Participants included 48 patients (23 females) with schizophrenia
(DSM-IV-TR Criteria) and 50 healthy controls (25 females) recruited
from three academic sites including the University of California-San
Diego, the University of Miami - Miller School of Medicine, and the Uni-
versity of South Carolina. All participants were screened for alcohol and
substance abuse using modules J and K of the MINI InternationalPlease cite this article as: Atkins, A.S., et al., Validation of the tablet-adminis
http://dx.doi.org/10.1016/j.schres.2016.10.010Neuropsychiatric Interview. Any subject meeting criteria for current al-
cohol or substance abuse was excluded. All subjects provided signed in-
formed consent prior to completion of study-related activities.
Detailed demographic information is displayed in Table 1. To ensure
adequate sampling to support validation of the BAC App across age and
sex demographics, enrollment was stratiﬁed to include balanced repre-
sentation ofmen andwomen in eachof 6 age groups: 18–29, 30–39, 40–
49, 50–59, 60–69, 70+. In addition, study investigatorsmade a concert-
ed effort to match patients and controls on age, sex and race. As indicat-
ed in Table 2, groups were well matched on each of these variables and
on maternal education. Patients and controls differed signiﬁcantly with
respect to years of education attained (p b 0.001).
2.2. Design and procedure
All subjects completed the BAC App and the Paper BAC assessments
at a single study visit, with order of administration counterbalanced
across subjects. For subtests with multiple forms (Verbal Memory,
Tower of London, Symbol Coding), alternate versionswere utilized dur-
ing administration of the tablet and paper-based tests. As such, noword
list memoranda, Tower of London item or Symbol Coding conﬁguration
was completed more than once for any participant.
Following informed consent procedures, participants completed a
brief demographic and medical history questionnaire. Participants
were screened for current alcohol and substance abuse to ensure eligi-
bility prior to testing. The BAC App and Paper BAC tests were then ad-
ministered by trained raters. Following completion of both
assessments, subjects completed a brief questionnaire to provide sub-
jective ratings of their experienceswith the BACApp. Finally, all subjects
were administered two measures of functional capacity, including the
Virtual Reality Functional Capacity Assessment Tool (Ruse et al., 2014;
Atkins et al., 2015) and the UCSD Performance-based Skills Assessment
(Patterson et al., 2001) not discussed here. The study visit lasted ap-
proximately 3 h, including screening. Participants received a $50 gift
card as compensation for their time and effort.
2.2.1. BAC App method
Detailed descriptions of the Paper BAC tests can be found in previous
publications (e.g. Keefe et al., 2004, 2006, 2008). The BAC app is a tablet-
based version of the instrument developed for use on an iPad© tablet.
Subtests within the BAC App can be administered in sequence as a full
battery, as presented here, or the App can be conﬁgured to allow for ad-
ministration of a smaller selection of tests and/or customized test order.
In order to facilitate repeated testing and reduce practice effects, alter-
nate versions are available for several BAC App subtests, including Ver-
bal Memory (7 versions), Symbol Coding (8 versions), and Tower of
London (8 versions).
All tests administered within the BAC App are completed under the
supervision of a trained rater. Instructions for each subtest are present-
ed by a female narrator within the App, ensuring consistent and accu-
rate administration. The rater can initiate repetition of instructions
through the touch screen to ensure adequate understanding by the sub-
ject prior to task initiation. The electronic tablet device is passed be-
tween the rater and the subject during testing.tered Brief Assessment of Cognition (BACApp), Schizophr. Res. (2016),
Table 2
Mean performance of BAC app and Paper BACS in healthy controls and patients with schizophrenia.
Schizophrenia Healthy controls
dApp dPaper
BAC app
(mean ± SD)
Paper BAC
(mean ± SD) Cohen's d p-ValueSCZ
BAC app
(mean ± SD)
Paper BAC
(mean ± SD) Cohen's d p-ValueHC
Verbal Memory 32.47 ± 10.39 33.02 ± 9.49 −0.06 0.74 42.68 ± 10.59 43.22 ± 10.73 −0.06 0.80 0.97 1.02
Digit Sequencing 15.84 ± 4.03 17.02 ± 3.86 −0.30 0.15 19.52 ± 4.48 20.24 ± 4.00 −0.17 0.40 0.87 0.83
Verbal Fluency 42.09 ± 13.45 42.94 ± 13.15 −0.06 0.66 57.02 ± 12.63 53.74 ± 12.92 0.26 0.34 1.16 0.84
Symbol Coding 32.65 ± 14.01 43.02 ± 12.60 −0.79 0.0002 46.2 ± 15.99 55.82 ± 14.75 −0.63 0.002 0.91 0.94
Token Motor Task 45.42 ± 27.02 46.79 ± 13.06 −0.07 0.75 72.56 ± 31.49 60.28 ± 14.22 0.51 0.01 0.93 1.00
Tower of London 13.62 ± 4.08 13.54 ± 5.12 0.02 0.87 16.44 ± 4.27 16.14 ± 4.20 0.07 0.72 0.63 0.56
Composite 25.96 ± 14.72 29.90 ± 14.40 −0.27 0.19 47.00 ± 16.98 46.76 ± 12.95 0.02 0.94 1.34 1.25
Modiﬁed composite 31.75 ± 13.36 33.35 ± 13.75 −0.12 0.56 48.22 ± 13.72 48.38 ± 12.76 −0.01 0.95 1.23 1.15
p-ValueHC = signiﬁcance value for BAC App vs Paper BAC in healthy controls, by t-test (two sample independent); p-ValueSCZ = signiﬁcance value for BAC App vs Paper BAC in patients
with schizophrenia, by t-test.
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The audio recording feature is enabled on all tests requiring verbal re-
sponses, including Verbal Memory, Digit Sequencing, Semantic and Let-
ter Fluency. In order to ensure accurate scoring of these tests, the rater is
given the opportunity to review the audio ﬁles and conﬁrm scoring at
the end of test administration.
Following is a description of the six subtests of the BAC App:
Verbal Memory (Verbal Memory & Learning Domain): Subjects hear a
list of 15words to remember.Words are presented by theApp in at a
standard rate, eliminating the effects of rater variability. Alternative
forms available: 7.
Outcomemeasure: Total number of words recalled across 5 learning
trials.
Completion time: 7 min.
Digit Sequencing (Working Memory Domain): Subjects are presented
with randomly ordered auditory clusters of numbers (e.g. 936) with
steadily increasing trial length. As in Verbal Memory, items are pre-
sented by the App at a standard rate, eliminating the effects of rater
variability. Subjects are asked to report the numbers in order, from
lowest to highest.
Outcomemeasure: Number of trials with all items in the correct order.
Completion time: 5 min.
Token Motor Task (Motor Function): Subjects are presented with a
virtual bowl and a supply of virtual tokens and asked to swipe a
token from each side of the tablet with the index ﬁnger from each
hand simultaneously and release them into the center container as
rapidly as possible for 60 s.
Outcome measure: Number of tokens correctly dragged into the
container.
Completion time: 3 min.
Semantic Fluency & Letter Fluency Tasks (Verbal Fluency Domain):
During Semantic Fluency, subjects are given 60 s to generate as
many words as possible within the category ‘animals’. During Letter
Fluency, subjects are asked to generate as many words as possible
beginning with a given letter. Subjects are administered two trials
using letters F and S.
Outcome measures: Total words generated for each ﬂuency task.
Total scores fromboth tasks are combined to produce the Vernal Flu-
ency domain score.
Completion time: 5 min.
Symbol Coding (Speed of Processing): Subjects assign numbers to
non-meaningful symbols with the use of a key that is provided.
Numbers are entered on the digital keypad and appear in the loca-
tion below the corresponding symbol. Following instructions andPlease cite this article as: Atkins, A.S., et al., Validation of the tablet-adminis
http://dx.doi.org/10.1016/j.schres.2016.10.010practice, subjects are given 90 s to complete asmany items as possi-
ble. Alternative forms available: 8.
Outcomemeasure: Number items completed correctlywithin the 90
second test period.
Completion time: 3 min.
Tower of London (Executive Functions/Reasoning and Problem Solv-
ing): Subjects are shown two images presented on opposite sides
of the tablet screen. Each image shows a different conﬁguration of
3 colored balls arranged on 3 pegs. The subject is required to accu-
rately determine the total number of times the balls in one picture
would have to be moved in order to make the arrangement of balls
identical to that of the other, opposing picture, while employing
the standard rules employed in tower tests (balls are moved one at
a time and balls on top of other balls must be moved ﬁrst). Alterna-
tive forms available: 8.
Outcome measure: Number of correct responses.
Time: 7 min.
2.3. Data analyses
2.3.1. Composite scores
The primary outcomemeasure from the both the BAC App and Paper
BAC is a composite T score that averages the standardized scaled scores
fromeach of the six tests. The T-score is ametric for expressing standard
scores and has a mean of 50 and an SD of 10. Composite scores for the
Paper BAC and BAC App were computed using published normative
values for the paper version of the test (Keefe et al., 2008), with adjust-
ments for age and gender applied to T-scores for each subtest. The Com-
posite score for subjects with missing subtests was imputed using the
average of the remaining subtests.
2.3.2. Performance differences
Differences in performance on the BAC App and Paper BAC were
evaluated using the t-test and Cohen's d. Between-group comparisons
(t-test and Cohen's d) assessed the effectiveness of the BAC App and
Paper BAC in distinguishing between patients and healthy controls.
Pearson correlations between the BAC App and Paper BAC domains
were calculated to determine correspondence between performance
on the Paper BAC and BAC App versions of each test, as well as the sum-
mary composite scores derived from paper and iPad based assessments.
After comparing the T-scores for each subtest and the composite be-
tween theBACApp and Paper BAC, amodiﬁed compositewas calculated
(see the Results and Discussion sections). Themodiﬁed composite score
included a 10-point addition to the BAC app symbol coding and removal
of the token motor subtest. R-squared was calculated to measure the
correlation between the BAC app and Paper BAC modiﬁed composite
scores.tered Brief Assessment of Cognition (BACApp), Schizophr. Res. (2016),
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3.1. Completion rate
One patient was unable to complete the BAC App Tower of London
assessment due to a lack of understanding of the task. For three healthy
controls and one patient, the BAC App Verbal Fluency subtest scores
were missing due to an administration error. BAC App Verbal Memory
data was missing for one patient due to an administration error. For
all cases with missing data, composite scores were imputed using the
average of the remaining tests.
3.2. Performance differences
Table 2 displays means and standard deviations for healthy controls
and schizophrenia patients on each subtest in the BAC App and Paper
BAC. In both groups, the distributions of standardized composite scores
for the BAC App and Paper BAC were indistinguishable, and the be-
tween-methods mean differences were not statistically signiﬁcant
(Table 2). Signiﬁcant differences were found between the Paper BAC
and the BAC App in both groups for the symbol-coding test and for
the token motor test in the controls only, with the BAC app leading to
poorer performance on symbol coding and better performance on the
token motor test. For all other tests, the differences between methods
were small and not statistically signiﬁcant.
Effect sizes (Cohen's d) were also calculated between healthy con-
trols and patients with schizophrenia within BAC app and Paper BACS.
The discrimination between patients and controls was similar for com-
posite scores from the BAC App (d = 1.34) and the Paper BAC (d =
1.25). Each test in the BAC App demonstrated sensitivity to cognitive
deﬁcits in the schizophrenia group, with patients signiﬁcantly
underperforming controls (see Fig. 1).
3.3. Correlations between BAC app and Paper BAC measures
The correlations between the BAC app and Paper BAC measures for
healthy controls and patients with schizophrenia are presented in
Table 3. In healthy controls, correlations between BAC App and Paper
BACmeasureswere greater than r=0.70 (p b 0.01) for VerbalMemory,
Digit Sequencing, Verbal Fluency, Symbol Coding and Tower of London.
The Paper BAC and BAC App versions of the Token Motor Task were
more modestly correlated (r = 0.47, p b 0.01), reﬂecting the consider-
able differences between the ﬁnger swipe action required by the BAC
App and the manual manipulation of tokens in the original Paper BAC.
The magnitude of correlations between the BAC App and the Paper
BACwas similar in the patient group: VerbalMemory, Digit Sequencing,20
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Fig. 1. Sensitivity of BACAppmeasures to cognitive impairment in the schizophrenia group. For a
degree of these deﬁcits is comparable to deﬁcits observed using the traditional pen-and-paper
Please cite this article as: Atkins, A.S., et al., Validation of the tablet-adminis
http://dx.doi.org/10.1016/j.schres.2016.10.010and Verbal Fluency were correlated at r = 0.70 (p b 0.01) or greater,
though the correlation for the Tower of London task was slightly
lower at r = 0.61 (p b 0.01). As with healthy controls, the correlation
was lowest for the Token Motor Task (r = 0.43, p b 0.01) suggesting
both populations were sensitive to differences in task demands be-
tween the Paper BAC and BAC App versions of this test.
3.4. Modiﬁcation of BAC App and Paper BAC composite scores
Composite scores for the Paper BAC and BAC App were computed
using published normative values for the paper version of the test
(Keefe et al., 2008). Using this method, the correlation between BAC
App and Paper BAC composite scores for healthy controls was r =
0.86 and for patients r = 0.77 (Fig. 2a). Observed differences between
the Paper BAC and BAC App on the symbol coding and tokenmotor sub-
tests (see Table 2) prompted further consideration of the equivalency of
the paper- and tablet-based version of these measures. For the symbol
coding subtest, a 10-point difference was observed between the two
methods in both patients, though the standard deviations for the mea-
sures were equivalent in both groups. For the token motor test, differ-
ences were more substantial and were marked by low correlations in
both patients and controls (p b 0.50) as well as increased variability in
the BAC App version of the measure. In order to address these issues, a
modiﬁed composite score for the BAC App was produced to improve
test equivalency in the absence of a full set of normative data for the
BAC App. Modiﬁcation included a raw score adjustment of 10 points
(+10) to BAC App raw scores for the symbol coding task and removal
of token motor subtest from both BAC App and Paper BAC composite
calculations. The correlation between modiﬁed composite scores for
the BAC App and Paper BACwas r=0.88 (p b 0.001) in healthy controls
and r = 0.89 (p b 0.001) in patients (Fig. 2b), which is consistent with
the test-retest reliability of the Paper BAC measure (Keefe et al., 2004).
Fig. 3 presents the overlap histograms of themodiﬁed composite scores.
Distributions of modiﬁed composite scores were nearly identical for the
BAC App and the Paper BAC in both healthy controls (Fig. 3a) and pa-
tients with schizophrenia (Fig. 3b). Modiﬁed composite score for both
the BAC App and Paper BAC demonstrated strong discrimination be-
tween patients and controls (Fig. 3c and d, respectively), indicating
the modiﬁed composite is effective in increasing test equivalency
while preserving sensitivity to cognitive impairments in the patient
group.
3.5. Testing order
In order to evaluate the inﬂuence of testing order on observed re-
sults, BAC App modiﬁed composite scores and Paper BAC compositerbal 
ency
Symbol Coding Tower of 
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Composite Score 
(not modified) 
.70
26.90
39.79
25.96
ll BACApp subtests, patients performedapproximately 1–2 SDbelowhealthy controls. The
BACS (e.g. Keefe et al., 2004).
tered Brief Assessment of Cognition (BACApp), Schizophr. Res. (2016),
Table 3
Pearson correlations between BAC App and Paper BAC tests in healthy controls and schizophrenia patients.
Healthy controls Schizophrenia patients
Paper BAC
BAC App BAC App
VM DS VF SC TM TL VM DS VF SC TM TL
VM 0.81⁎⁎ 0.39⁎⁎ 0.48⁎⁎ 0.55⁎⁎ 0.60⁎⁎ 0.41⁎⁎ 0.78⁎⁎ 0.56⁎⁎ 0.52⁎⁎ 0.46⁎⁎ 0.11 0.58⁎⁎
DS 0.43⁎⁎ 0.83⁎⁎ 0.57⁎⁎ 0.43⁎⁎ 0.39⁎⁎ 0.46⁎⁎ 0.56⁎⁎ 0.80⁎⁎ 0.49⁎⁎ 0.33⁎ 0.24 0.33⁎
VF 0.48⁎⁎ 0.66⁎⁎ 0.78⁎⁎ 0.42⁎⁎ 0.46⁎⁎ 0.48⁎⁎ 0.47⁎⁎ 0.52⁎⁎ 0.93⁎⁎ 0.41⁎⁎ 0.25 0.46⁎⁎
SC 0.36⁎ 0.49⁎⁎ 0.37⁎ 0.74⁎⁎ 0.68⁎⁎ 0.46⁎⁎ 0.49⁎⁎ 0.41⁎⁎ 0.57⁎⁎ 0.72⁎⁎ 0.48⁎⁎ 0.49⁎⁎
TM 0.28⁎ 0.36⁎⁎ 0.29 0.47⁎⁎ 0.47⁎⁎ 0.32⁎ 0.21 0.29⁎ 0.48⁎⁎ 0.48⁎⁎ 0.43⁎⁎ 0.36⁎
TL 0.36⁎ 0.37⁎⁎ 0.39⁎⁎ 0.37⁎⁎ 0.43⁎⁎ 0.74⁎⁎ 0.51⁎⁎ 0.36⁎ 0.31⁎ 0.26 0.01 0.61⁎⁎
BAC measures: VM= Verbal Memory; DS = Digit Sequencing; VF = Verbal Fluency; SC = Symbol Coding; TM= Token Motor Task, TL = Tower of London.
Bolded items represent correlations between Paper BAC and BAC App versions of each test.
⁎ p b 0.05.
⁎⁎ p b 0.01.
5A.S. Atkins et al. / Schizophrenia Research xxx (2016) xxx–xxxscores were entered into a mixed model for repeated measures
(MMRM) with Test Modality (tablet vs. paper) and with Test Order
(BAC App ﬁrst or second) as a between subject variable. Results indicat-
ed no main effect for the order in which tests were given (p = 0.62),
though a Test Modality by Test Order interaction demonstrated that,
as expected, subject's performed better on the second test administered
(F = 22.75, p b 0.001). As such, subjects who completed the BAC App
ﬁrst demonstrated improvement on the Paper BAC (administered sec-
ond) and subjects who completed the Paper BACﬁrst demonstrated im-
provement on the BAC App.-40
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Fig. 2. Scatterplot of BAC App and Paper BAC unmodiﬁed (panel A) and modiﬁed* (panel
B) composite scores for schizophrenia patients and controls. *Note: Modiﬁed composite
scores incorporated a 10-point adjustment to the BAC App Symbol Coding raw score
prior to standardization, and elimination of the Token Motor Test from composite
calculations for both the BAC App and Paper BAC.
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http://dx.doi.org/10.1016/j.schres.2016.10.0103.6. Correlations with the Virtual Reality Functional Capacity Assessment
Tool (VRFCAT)
The correlations between the BACApp and the VRFCAT, a computer-
based measure of functional capacity, were robust for healthy controls
(r = 0.69) and for patients (r = 0.61). These correlations were slightly
larger than those found between the VRFCAT and the Paper BAC in
healthy controls (r = 0.62) and patients (r = 0.46).4. Discussion
Theprimary aimof the present validation studywas to assess the va-
lidity of the BAC App as a measure of cognitive function by examining
performance on the BAC App and comparing it to performance on the
original Paper BAC. The BAC App allows tablet-based delivery and scor-
ing of 5 key subtests for the assessment of cognitive impairment includ-
ed in the original pen and Paper BAC. By ensuring standardized
administration of instructions and test stimuli, the BAC App allows for
reduction in error variance due to rater inconsistencies, and provides
automated scoring, yet maintains the participant-rater interactions in-
herent in human testing. The data from this study suggest that the
BACApphas very similar overall psychometric characteristics to the tra-
ditional Paper BAC. Speciﬁcally, the BAC App had nearly identical sensi-
tivity to the overall cognitive deﬁcits measured by a composite score
comparingpatientswith schizophrenia to healthy controls. The comple-
tion rate with the BAC App was very high, with very few missing data
points, in contrast to computerized technology that historically has led
to a signiﬁcantly increased missing data rate (Silver et al., 2006;
Harvey et al., 2013; Keefe et al., 2007a; Iverson et al., 2009). Finally,
the BAC App demonstrated strong correlations with scores on the
VRFCAT, a measure of functional capacity, suggesting that the BAC
App, like the BAC, measures aspects of cognition that are relevant for
the performance of everyday functional tasks.
Most cognitive tests included in the BAC App demonstrated very
high correlations with the tests from the Paper BAC. These tests includ-
ed Verbal Memory, Digit Sequencing, Tower of London, and Verbal Flu-
ency. The consistency of results for these tests is natural and expected in
light of minimal change in testing methodology between the Paper BAC
and the BACApp. In contrast, the testmethod for the symbol coding test
varies considerably between the Paper BAC and the BACApp, the former
requiring written responses and the latter requiring the use of a digital
keypad. Despite these variations, the decrement in performance from
the Paper BAC to the BAC App was fairly linear with correlations N0.70
in both groups and a 10-point difference between the two methods in
each group. Thus, a 10 point correction to the BAC App score enables
use of the original BAC norms with minimal validity concerns. The
methodology for the BACAppTokenMotor Test also varies considerably
from that employed by the Paper BAC. In the Paper BAC, subjects are re-
quired tomanipulate real plastic tokens by lifting them off of a table andtered Brief Assessment of Cognition (BACApp), Schizophr. Res. (2016),
Fig. 3. Overlapping distributions of BAC app and Paper BAC composite scores for patients and healthy controls are displayed in panels a and b, respectively. Distributions for both
participant group on the BAC app and Paper BAC are displayed in panels c and d, indicating the sensitivity of both instruments to group differences.
6 A.S. Atkins et al. / Schizophrenia Research xxx (2016) xxx–xxxplacing them into a container. By comparison, the BAC App requires
subjects to swipe virtual ‘digital’ tokens and release them into a virtual
bowl. For this test, differences in methodology likely explain the lower
correlations observed between the Paper BAC and BAC App in both
healthy controls and patients with schizophrenia (r b 0.50), as well as
larger standard deviations for the BAC App version, and mean differ-
ences between the methodologies in the patient group. It is also likely
that prior experience with tablet applications may be more predictive
of performance on this test than any of the other tests. Future studies
will need to establish normative performance for the BAC App version
of the Token Motor Test, since the current norms are not applicable.
While the ability to swipe a screen is an important functional skill, use-
ful for both tablet devices and mobile phones, variability in this skill
leads to divergent performance between the BAC App and the Paper
BAC.
The creation of a composite score for the BAC App using previously
published norms for the Paper BAC reﬂects very similar performance if
a 10-point correction is made for the symbol coding test and the
Token Motor Test is not included. This 5-test composite score was
found to be correlated with the Paper BAC composite score with values
of 0.89 for controls and 0.88 for patients, which is almost identical to the
test-retest reliability of the Paper BAC. Thus, this score should be a useful
psychometric index of cognitive functioning in patients with schizo-
phrenia, based upon age- and sex-corrected values from the healthy
population. Further, the strong correlation of 0.61 with a measure ofPlease cite this article as: Atkins, A.S., et al., Validation of the tablet-adminis
http://dx.doi.org/10.1016/j.schres.2016.10.010functional capacity, the VRFCAT, in patients with schizophrenia is con-
sistentwith previous reports on the correlation betweenother tests bat-
teries, such as the MCCB, with traditional measures of functional
capacity such as the UCSD Performance-based Skills Assessment
(Leifker et al., 2010).
There are a few limitations to this study. First, the sample size for this
study was relatively small for a validation study. Although the results
were very clear, and larger sampleswould be unlikely to reach alternate
conclusions, larger samples would provide better reﬂection of the over-
all population, establish the test-retest reliability of the BAC App, and
enable an investigation of the different demographic factors that may
affect performance on a tablet-based cognitive test battery. Such studies
are underway. Second, although we expect that the standardized ad-
ministration provided by the BAC Appmay increase data quality in clin-
ical trials employing raters of varying expertise, the present
investigation cannot speak directly to this point. Finally, although
every effort was made to ensure impartial data collection and analysis,
funding for the current studywas provided by a companywith ﬁnancial
interest in the BAC and BAC App. Replication by independent research
groups will be important to conﬁrm the validity and usefulness of the
BAC App.
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